Department of Pediatric Allergy, Medical Faculty, Hacettepe University, Ankara, Turkey
Turk J Med Sci. 2019 Aug 8;49(4):1008-1013. doi: 10.3906/sag-1812-133.
BACKGROUND/AIM: The aim of this study was to compare the effect of salbutamol delivered to children by jet nebulizer (JN) and mesh nebulizer (MN).
Children admitted with acute asthma were treated with 3 doses of nebulized salbutamol, 1 given by MN. The patients’ vital signs, lung function measurements, modified pulmonary index score (MPIS), and whole body plethysmography (WBP) measurements were evaluated before and 20 min after each dose of salbutamol.
Thirty-onechildren [9.5 (6.4–17.2) years, 67.7% male, 32.3% female] with mild (67.7%) and moderate (32.3%) asthma attacks were included in the study. The improvements with MN were comparable with JN in terms of changes in pretreatment and posttreatment forced expiratory volume in the first second (FEV1) (2.57 ± 4.57, 3.65 ± 5.44; P = 0.44), forced vital capacity (FVC) (2.52 ± 5.29, 4.17 ± 7.54; P = 0.28), heart rate (7.33 ± 10.21, 4.14 ± 9.32; P = 0.24), peripheral capillary oxygen saturation (SpO2) (0.38 ± 0.23, 0.43 ± 0.15; P = 0.83), and modified pulmonary index score (MPIS) (−6.30 ± 22.70, −8.77 ± 25.46; P = 0.70). The pre- and posttreatment values of total lung capacity (TLC), residual volume (RV), specific conductance (sGaw), and RV/TLC were similar for the JN and MN groups. Adverse effects were not different: however, complaints of palpitation were significantly higher in the posttreatment MN group than the pretreatment MN group (32.3% vs 9.7%, respectively, P = 0.016).
These findings support the previous evidence found in studies of adults that MN is as effective as and as safe as JN in the treatment of acute asthma in children
背景/目的:本研究旨在比较沙丁胺醇通过射流雾化器(JN)和网孔雾化器(MN)输送给儿童的效果。
患有急性哮喘的患儿接受 3 次雾化沙丁胺醇治疗,其中 1 次由 MN 给予。在每次沙丁胺醇给药前和给药后 20 分钟评估患儿的生命体征、肺功能测量、改良肺部指数评分(MPIS)和全身体积描记术(WBP)测量值。
31 名儿童(9.5(6.4-17.2)岁,67.7%为男性,32.3%为女性),轻度(67.7%)和中度(32.3%)哮喘发作,纳入研究。MN 组的改善与 JN 组在预处理和后处理第 1 秒用力呼气量(FEV1)(2.57 ± 4.57,3.65 ± 5.44;P = 0.44)、用力肺活量(FVC)(2.52 ± 5.29,4.17 ± 7.54;P = 0.28)、心率(7.33 ± 10.21,4.14 ± 9.32;P = 0.24)、外周毛细血管血氧饱和度(SpO2)(0.38 ± 0.23,0.43 ± 0.15;P = 0.83)和改良肺部指数评分(MPIS)(-6.30 ± 22.70,-8.77 ± 25.46;P = 0.70)方面相当。JN 和 MN 组的总肺容量(TLC)、残气量(RV)、比气道传导率(sGaw)和 RV/TLC 的预处理和后处理值相似。不良反应无差异:然而,MN 组治疗后心悸的发生率明显高于治疗前(32.3% vs 9.7%,P = 0.016)。
这些发现支持先前在成人研究中发现的证据,即 MN 与 JN 一样有效且安全,可用于治疗儿童急性哮喘。